Seven Chinese Pharmaceutical Companies Reappear on the 2024 Hurun Rich List

Source:Hurun Research Institute整理：Crystal

October 29,Hurun ResearchThe hospital released"2024 Hengchang Shaofang · Hurun Rich List"

Founder of Nongfu SpringZhong Shanshan's wealth decreased by 110 billion yuan last year, and with 340 billion yuan, he relinquished the top position as the richest person that he had held for three years, ranking second.CharacterZhang Yiming, 41, of ByteDance has become China's richest person for the first time with a wealth of 350 billion yuan. 

A total of 7 pharmaceutical companies made the list, all familiar names. Among them, the wealth of 2 pharmaceutical companies decreased compared to last year, while the wealth of the other 5 companies saw positive growth. Two of the companies experienced significant wealth growth.Zhong Huijuan of Hansoh Pharma and Zhu Yi of Baili Tianheng。

This year,The industry with the number of people who failed to make the list is industrial products, accounting for 16%;Next is the pharmaceuticals industry, accounting for 11%.。 

Seven Pharma Companies Make the Hurun Rich List Again

Nongfu Spring, ranked second, its helmsman Zhong Shanshan has attracted attention with a wealth of 340 billion yuan. Nongfu Spring, as a well-known beverage enterprise in China, occupies an important market share in many fields such as drinking water and tea beverages. Its brand influence is extensive, product quality is excellent, and it is deeply loved by consumers. At the same time, under Zhong Shanshan's command, there are also pharmaceutical enterprises like Wantai Bio. Wantai Bio has achieved remarkable results in the field of pharmaceutical research and development, especially making significant breakthroughs in vaccine research, laying a solid foundation for the accumulation of his wealth.

Zhong Huijuan of Hansoh Pharma ranked 42nd with a wealth of 77 billion yuan.Hansoh Pharma has a rich product line in disease areas such as anti-tumor, anti-infection, and central nervous system. The company has consistently committed to the research and development of innovative drugs, dedicating substantial resources to scientific research, continuously launching competitive pharmaceuticals, and securing a significant position in the pharmaceutical market.

Sun Piaoyang of Hengrui Pharmaceutical ranked 55th with a wealth of 65 billion yuan.Hengrui Pharmaceutical is a well-known supplier of anti-tumor drugs and surgical medications in China. Over the years, Hengrui has consistently adhered to innovation as its driving force, continuously increasing R&D investment, and has launched a series of innovative drugs in major disease areas such as anti-tumor treatment.

Xu Haoyu's family from Yangtze River Pharmaceutical ranks 57th with a wealth of 63 billion yuan.Yangtze River Pharmaceutical is renowned for producing high-quality medicines, covering multiple therapeutic areas. The company emphasizes product quality and innovation, maintaining strict control over R&D, production, and sales processes, earning widespread market recognition and patient trust.

The Zhu Baoguo family of Jiankang Yuan ranked 59th with a wealth of 62 billion yuan.Healthcare has a wide range of layouts in the pharmaceuticals and health products fields. The company possesses strong capabilities in drug research, development, and production in areas such as respiratory and digestive health.

Cen Junda of Hengrui and Hansoh Pharma ranked 62nd with a wealth of 61 billion yuan.Jun Cen has an excellent vision and rich experience in pharmaceutical investment, playing a significant role in promoting the development of Hengrui Pharmaceutical and Hansoh Pharma.

Zhu Yi of Baili Tianheng ranks 74th with a wealth of 51 billion yuan.Although relatively less well-known compared to other pharmaceutical companies, Baili Tianhe has its own unique features and advantages in the pharmaceutical field, continuously making progress in specific pharmaceutical niche markets.

  

Zhong Shanshan of Nongfu Spring，Ranked Second

Founder of Nongfu SpringZhong Shanshan's wealth shrank by 110 billion yuan compared to last year, ranking second;Mainly due to the slowdown in Nongfu Spring's performance growth in the second quarter of this year.Since the end of February this year, online public opinion has had a negative impact on its brand and sales, causing the revenue of Nongfu Spring's packaged drinking water products to fall for the first time.

Another company under the group, Wantai Bio, previously experienced a period of deep adjustment last year due to industry impacts; this yearThe performance of Wantai Bio is also impacted by the fiercely competitive market for its bivalent cervical cancer vaccine business.

Zhong Huijuan, Zhu YiWealth Growth Increased

Zhong Huijuan of Hansoh Pharma and Zhu Yi of Baili Tianheng have performed well in the past year. Wealth 77 billion yuan,Zhong Huijuan of Hansoh Pharma (increased by 35 billion) andWealth 51 billion yuan,Zhu Yi of Baili Tianheng (increased by 24 billion).

1. Hansoh Pharma:As a leading innovative pharmaceutical enterprise in China, Hansoh Pharma currently has 7An innovative drug has been approved for marketing and included in medical insurance.

On October 24, the latest announcement on the CDE website revealed that Hansoh Pharma's HS-20093 for injection is proposed to be included in the breakthrough therapy designation. The proposed indication is: extensive-stage small cell lung cancer (ES-SCLC) that has progressed after standard first-line treatment (platinum doublet chemotherapy combined with immunotherapy). Public information indicates that HS-20093 is a B7-H3-targeted antibody-drug conjugate (ADC) developed by Hansoh Pharma.

Public information shows that more than ten clinical studies of HS-20093 are currently underway, including two Phase 3 clinical studies for recurrent small cell lung cancer and limited-stage small cell lung cancer, as well as multiple Phase 1 and Phase 2 clinical studies for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors.

In December 2023, Hansoh Pharma entered into an exclusive licensing agreement worth over $1.7 billion with GSK, granting the latter global exclusive rights (excluding Greater China) to develop, manufacture, and commercialize HS-20093.

In August this year, GSK announced that HS-20093 had received the FDA Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory ES-SCLC who progressed during or after platinum-based chemotherapy. The FDA Breakthrough Therapy Designation was supported by data from the Phase 1 ARTEMIS-001 first-in-human clinical trial.

2. Baili TianhengThe growth was mainly driven byAt the end of last year, Hansoh Pharma reached an agreement with Bristol-Myers Squibb, a Fortune 500 company ranked by Hurun in the United States, to license the global rights (excluding China) of a new drug developed by the former to the latter.

Affected pharmaceutical companies

Affected by U.S. policies, such as Li Ge from Wuxi AppTec; some are due to products being highly related to the COVID-19 pandemic, with significant differences in sales before and after the pandemic, impacting their performance in the secondary market, such as Jiang Rensheng from Zhifei Biological Products, and Wu Yiling from Yiling Pharmaceutical.

This year marks the 26th consecutive release of the "Hurun Rich List" by the Hurun Research Institute since 1999.The cut-off date for calculating the wealth of listed entrepreneurs is August 30, 2024.